JP2018513852A5 - - Google Patents

Download PDF

Info

Publication number
JP2018513852A5
JP2018513852A5 JP2017552451A JP2017552451A JP2018513852A5 JP 2018513852 A5 JP2018513852 A5 JP 2018513852A5 JP 2017552451 A JP2017552451 A JP 2017552451A JP 2017552451 A JP2017552451 A JP 2017552451A JP 2018513852 A5 JP2018513852 A5 JP 2018513852A5
Authority
JP
Japan
Prior art keywords
sodium
pharmaceutical composition
ibrutinib
composition according
microcrystalline cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017552451A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513852A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/026134 external-priority patent/WO2016164404A1/en
Publication of JP2018513852A publication Critical patent/JP2018513852A/ja
Publication of JP2018513852A5 publication Critical patent/JP2018513852A5/ja
Priority to JP2021181761A priority Critical patent/JP7438178B2/ja
Priority to JP2023193108A priority patent/JP2024026087A/ja
Withdrawn legal-status Critical Current

Links

JP2017552451A 2015-04-06 2016-04-06 イブルチニブを含有する組成物 Withdrawn JP2018513852A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021181761A JP7438178B2 (ja) 2015-04-06 2021-11-08 イブルチニブを含有する組成物
JP2023193108A JP2024026087A (ja) 2015-04-06 2023-11-13 イブルチニブを含有する組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562143659P 2015-04-06 2015-04-06
US62/143,659 2015-04-06
PCT/US2016/026134 WO2016164404A1 (en) 2015-04-06 2016-04-06 Compositions containing ibrutinib

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021181761A Division JP7438178B2 (ja) 2015-04-06 2021-11-08 イブルチニブを含有する組成物

Publications (2)

Publication Number Publication Date
JP2018513852A JP2018513852A (ja) 2018-05-31
JP2018513852A5 true JP2018513852A5 (https=) 2019-05-16

Family

ID=55806788

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017552451A Withdrawn JP2018513852A (ja) 2015-04-06 2016-04-06 イブルチニブを含有する組成物
JP2021181761A Active JP7438178B2 (ja) 2015-04-06 2021-11-08 イブルチニブを含有する組成物
JP2023193108A Pending JP2024026087A (ja) 2015-04-06 2023-11-13 イブルチニブを含有する組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021181761A Active JP7438178B2 (ja) 2015-04-06 2021-11-08 イブルチニブを含有する組成物
JP2023193108A Pending JP2024026087A (ja) 2015-04-06 2023-11-13 イブルチニブを含有する組成物

Country Status (29)

Country Link
US (6) US20160287594A1 (https=)
EP (3) EP4272835A3 (https=)
JP (3) JP2018513852A (https=)
KR (2) KR20240013859A (https=)
CN (2) CN107530293A (https=)
AU (4) AU2016246669B2 (https=)
CA (1) CA2981601A1 (https=)
CL (1) CL2017002512A1 (https=)
DK (1) DK3892302T3 (https=)
EA (1) EA033992B1 (https=)
ES (1) ES2964472T3 (https=)
FI (1) FI3892302T3 (https=)
HK (1) HK1250925A1 (https=)
HR (1) HRP20231207T1 (https=)
HU (1) HUE063751T2 (https=)
IL (2) IL295941A (https=)
LT (1) LT3892302T (https=)
MA (2) MA54411B1 (https=)
MD (1) MD3892302T2 (https=)
MX (2) MX2017012822A (https=)
PH (1) PH12017501811A1 (https=)
PL (1) PL3892302T3 (https=)
PT (1) PT3892302T (https=)
RS (1) RS64653B1 (https=)
SG (2) SG10202103458QA (https=)
SI (1) SI3892302T1 (https=)
SM (1) SMT202300422T1 (https=)
UA (1) UA125681C2 (https=)
WO (1) WO2016164404A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210033067A (ko) 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
KR20170033358A (ko) 2014-08-07 2017-03-24 파마싸이클릭스 엘엘씨 브루톤 티로신 키나아제 저해제의 신규한 제제
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
HK1250925A1 (zh) 2015-04-06 2019-01-18 Janssen Pharmaceutica, N.V. 包含依鲁替尼的组合物
EP3523280B1 (en) 2016-10-06 2026-03-11 Janssen Pharmaceutica NV Processes and intermediates for preparing a btk inhibitor
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
CN108653231A (zh) * 2017-04-01 2018-10-16 北京赛林泰医药技术有限公司 含有布鲁顿酪氨酸激酶抑制剂的组合物及其制备方法
CN107014943B (zh) * 2017-06-07 2018-08-21 福建省微生物研究所 一种依鲁替尼对映异构体的检测方法
WO2019038584A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
TWI843707B (zh) 2017-09-26 2024-06-01 美商提薩羅有限公司 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物
CA3089537A1 (en) * 2018-01-20 2019-07-25 Natco Pharma Limited Pharmaceutical compositions comprising ibrutinib
KR20190122561A (ko) * 2018-04-21 2019-10-30 류형준 림프 순환 장애의 치료 또는 경감을 위한 약학적 조성물과 식품 조성물
BR112020024481A2 (pt) * 2018-06-15 2021-03-02 Janssen Pharmaceutica Nv formulações/composições compreendendo ibrutinib
WO2020039263A2 (en) 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage
WO2020039264A2 (en) * 2018-08-18 2020-02-27 Ftf Pharma Private Limited Chemotherapeutic pharmaceutical suspension for oral dosage
KR102198502B1 (ko) * 2018-09-16 2021-01-05 류형준 인체의 림프순환 개선을 위한 식품 조성물
EP3886992A1 (en) * 2018-11-30 2021-10-06 Janssen Biotech, Inc. Methods of treating follicular lymphoma
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
MX2022013797A (es) 2020-05-08 2022-11-30 Genmab As Anticuerpos biespecificos contra cd3 y cd20.
KR102251435B1 (ko) * 2020-11-09 2021-05-11 류형준 림프순환 촉진에 의한 부종 개선을 위한 식품 조성물
US11433072B1 (en) * 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib
WO2022260667A1 (en) * 2021-06-10 2022-12-15 Hikma Pharmaceuticals Usa Inc. Oral dosage forms of ibrutinib
CN117064862B (zh) * 2023-04-10 2025-12-19 山东新时代药业有限公司 一种伊布替尼肠溶片及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK607188A (da) 1987-11-02 1989-06-22 Merck & Co Inc Tablet indeholdende en phthalazineddikesyreforbindelse
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
DE10201304A1 (de) 2002-01-15 2003-07-31 Infineon Technologies Ag Nichtflüchtige Halbleiter -Speicherzelle sowie zugehöriges Herstellungsverfahren
EP1877059B8 (en) 2005-04-28 2010-05-19 Wyeth a Corporation of the State of Delaware Micronized tanaproget and compostions containing same
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8003309B2 (en) 2008-01-16 2011-08-23 International Business Machines Corporation Photoresist compositions and methods of use in high index immersion lithography
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
MX391121B (es) * 2011-10-19 2025-03-19 Pharmacyclics Llc Uso de inhibidores de la tirosina cinasa de bruton (btk).
KR20210033067A (ko) * 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
US20150140085A1 (en) 2012-06-29 2015-05-21 Principia Biopharma Inc. Formulations comprising ibrutinib
EP4223339B1 (en) 2013-03-14 2025-01-29 Fisher & Paykel Healthcare Limited Catheter mount with suction port
TWI609012B (zh) 2013-04-28 2017-12-21 廣東東陽光藥業有限公司 氨基喹唑啉類衍生物及其鹽和使用方法
WO2015022942A1 (ja) * 2013-08-12 2015-02-19 横浜ゴム株式会社 プライマー組成物
US9415050B2 (en) * 2013-08-12 2016-08-16 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
WO2015071432A1 (en) * 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
WO2015140709A1 (en) 2014-03-19 2015-09-24 Novartis Ag Solid pharmaceutical dosage forms
US20160032404A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
KR20170033358A (ko) 2014-08-07 2017-03-24 파마싸이클릭스 엘엘씨 브루톤 티로신 키나아제 저해제의 신규한 제제
CN104523695A (zh) * 2014-11-12 2015-04-22 广东东阳光药业有限公司 一种治疗过度增生性疾病的药物组合物
CN104407067B (zh) * 2014-11-17 2016-01-20 广东东阳光药业有限公司 依鲁替尼及其异构体的检测方法
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
HK1250925A1 (zh) 2015-04-06 2019-01-18 Janssen Pharmaceutica, N.V. 包含依鲁替尼的组合物
EP3463318A4 (en) 2016-05-27 2020-01-01 TG Therapeutics Inc. COMBINATION OF ANTI-CD20-ANTIBODIES, P13-KINASE-DELTA-SELECTIVE INHIBITOR AND BTK-INHIBITOR FOR THE TREATMENT OF PROLIFERATIVE B-CELL DISORDERS

Similar Documents

Publication Publication Date Title
JP2018513852A5 (https=)
AU2026200996A1 (en) Compositions containing Ibrutinib
HRP20201316T1 (hr) Novi modulatori receptora sfingozin-fosfata
US20110172210A1 (en) Method for titrating clozapine
FI3287124T3 (fi) Ketamiinin oraalinen annosmuoto
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
JP2018507243A5 (https=)
CA2802093A1 (en) Combination therapy with lisdexamphetamine and extended release guanfacine
RU2011152105A (ru) Составы таблеток 3-цианохинолина и их применение
KR20100008356A (ko) 칼슘채널길항제를 포함하는 약제학적 제제
WO2012173581A4 (en) Thiocolchicoside, etodolac and famotidine combinations
JP2021152060A (ja) アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
JP2011516544A5 (https=)
NO20062082L (no) Pellets inneholdende venlafaksinhydroklorid
NZ595798A (en) Ectoparasiticidal methods and formulations
JP2016505050A5 (https=)
MX2008011020A (es) Compuestos de receptor sigma.
HRP20151321T1 (hr) Epalrestat ili njegov derivat u oblicima s prilagođenim otpuštanjem te postupci uporabe istih
HRP20251123T1 (hr) Ekopipam za liječenje touretteovog sindroma
MY146102A (en) New citrate salt of an indole derivative and its pharmaceutical use
CA3091329A1 (en) Extended-release pharmaceutical composition containing lacosamide
KR101497354B1 (ko) 활성 성분으로 에페리손을 함유하는 서방성 제제 조성물
AU2007234917A1 (en) Renin inhibitors for the treatment of hypertension